| Primary |
| Pneumonia |
17.0% |
| Sepsis |
16.0% |
| Pyrexia |
8.7% |
| Meningitis |
8.3% |
| Infection |
4.4% |
| Urinary Tract Infection |
4.4% |
| Cystic Fibrosis |
3.9% |
| Antibiotic Prophylaxis |
3.4% |
| Chronic Obstructive Pulmonary Disease |
3.4% |
| Intervertebral Discitis |
3.4% |
| Respiratory Tract Infection |
3.4% |
| Epilepsy |
2.9% |
| Hypovitaminosis |
2.9% |
| Meningitis Bacterial |
2.9% |
| Prophylaxis |
2.9% |
| Pseudomonas Infection |
2.9% |
| Abdominal Sepsis |
2.4% |
| Postpartum Sepsis |
2.4% |
| Product Used For Unknown Indication |
2.4% |
| Cholangitis Acute |
1.9% |
|
| Pyrexia |
10.5% |
| Thrombocytopenia |
9.2% |
| Anaphylactic Reaction |
6.6% |
| Convulsion |
6.6% |
| Epilepsy |
6.6% |
| Poor Quality Drug Administered |
6.6% |
| Grand Mal Convulsion |
5.3% |
| Hepatitis |
5.3% |
| Pancytopenia |
5.3% |
| Renal Failure Acute |
5.3% |
| International Normalised Ratio Increased |
3.9% |
| Intravascular Haemolysis |
3.9% |
| Multi-organ Failure |
3.9% |
| Paraesthesia |
3.9% |
| Partial Seizures |
3.9% |
| Arthralgia |
2.6% |
| Bone Marrow Failure |
2.6% |
| Cellulitis |
2.6% |
| Drug Interaction |
2.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
14.6% |
| Infection Prophylaxis |
10.1% |
| Drug Use For Unknown Indication |
7.7% |
| Pain |
6.4% |
| Pyrexia |
6.4% |
| Sepsis |
5.9% |
| Antibiotic Prophylaxis |
4.8% |
| Renal Transplant |
4.5% |
| Lung Disorder |
4.3% |
| Hypertension |
4.0% |
| Endoscopic Retrograde Cholangiopancreatography |
3.7% |
| Infection |
3.7% |
| Prophylaxis |
3.5% |
| Thrombosis Prophylaxis |
3.5% |
| Urinary Tract Infection |
3.5% |
| Hypovitaminosis |
3.2% |
| Pneumonia |
2.9% |
| Sleep Disorder |
2.7% |
| Bacterial Sepsis |
2.4% |
| Nausea |
2.4% |
|
| Toxic Epidermal Necrolysis |
13.6% |
| Thrombocytopenia |
11.1% |
| Bone Marrow Failure |
7.4% |
| Cholestasis |
6.2% |
| Tremor |
6.2% |
| Multi-organ Failure |
4.9% |
| Poor Quality Drug Administered |
4.9% |
| Stevens-johnson Syndrome |
4.9% |
| Vanishing Bile Duct Syndrome |
4.9% |
| Agranulocytosis |
3.7% |
| Alanine Aminotransferase Increased |
3.7% |
| Arthralgia |
3.7% |
| Clostridium Difficile Infection |
3.7% |
| Off Label Use |
3.7% |
| Thrombotic Microangiopathy |
3.7% |
| Urticaria |
3.7% |
| Convulsion |
2.5% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.5% |
| Myositis |
2.5% |
| Pain In Extremity |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.3% |
| Product Used For Unknown Indication |
19.1% |
| Pneumonia |
7.6% |
| Diffuse Large B-cell Lymphoma |
5.5% |
| Sepsis |
4.6% |
| Hypertension |
4.3% |
| Prophylaxis |
4.3% |
| Pyrexia |
4.2% |
| Pain |
4.0% |
| Intensive Care |
3.3% |
| Thrombosis Prophylaxis |
3.0% |
| Aspergillosis |
2.7% |
| Acute Myeloid Leukaemia |
2.5% |
| Chronic Lymphocytic Leukaemia |
2.5% |
| Infection |
2.4% |
| Prostate Cancer |
2.0% |
| Pneumonia Bacterial |
1.7% |
| Cystic Fibrosis |
1.4% |
| Febrile Neutropenia |
1.4% |
| Prophylaxis Against Renal Transplant Rejection |
1.4% |
|
| Sepsis |
11.7% |
| Thrombocytopenia |
10.4% |
| Toxic Epidermal Necrolysis |
9.7% |
| Vomiting |
9.1% |
| Respiratory Failure |
7.8% |
| Septic Shock |
7.1% |
| Pneumonitis |
5.2% |
| Drug Ineffective |
4.5% |
| Systemic Inflammatory Response Syndrome |
4.5% |
| Myocarditis |
3.9% |
| Renal Failure |
3.9% |
| Death |
3.2% |
| Swelling |
3.2% |
| Coma |
2.6% |
| Pyrexia |
2.6% |
| Vanishing Bile Duct Syndrome |
2.6% |
| Encephalopathy |
1.9% |
| Hallucination |
1.9% |
| Hepatitis |
1.9% |
| Hypotension |
1.9% |
|
| Interacting |
| Respiratory Tract Infection |
21.1% |
| Sepsis |
21.1% |
| Pneumonia |
10.5% |
| Psychotic Disorder Due To A General Medical Condition |
10.5% |
| Urinary Tract Infection |
10.5% |
| Depression |
5.3% |
| Epilepsy |
5.3% |
| Factor V Leiden Mutation |
5.3% |
| Muscle Spasms |
5.3% |
| Product Used For Unknown Indication |
5.3% |
|
| Serotonin Syndrome |
40.0% |
| Drug Interaction |
20.0% |
| Rash Macular |
20.0% |
| Status Epilepticus |
20.0% |
|
